BC Week In Review | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...
BC Extra | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Wednesday after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and...
BC Extra | Jun 1, 2016
Top Story

Jazz acquiring Celator for $1.5B

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is to acquire Celator Pharmaceuticals Inc. (NASDAQ:CPXX) for $30.25 per share, or about $1.5 billion in cash. The price is a 73% premium on its Friday close of $17.53, and a...
BC Week In Review | Aug 24, 2015
Company News

Public Health England cancer news

Public Health England spun out its drug development and production activities into state-owned Porton Biopharma Ltd. The newco, which will employ over 200 people, manufactures leukemia drug Erwinase , an Erwinia chrysanthemi-derived L-asparaginase, and an anthrax...
BioCentury | Mar 30, 2015
Finance

Aeglea's crossover

The series B syndicate assembled by Aeglea Biotherapeutics Inc. has the hallmarks of a pre-IPO round. With a lead therapeutic enzyme on the brink of entering the clinic for Orphan diseases and cancer metabolism, the...
BioCentury | Nov 10, 2014
Finance

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
BioCentury | Aug 11, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
BC Extra | Aug 7, 2014
Financial News

Jazz to raise $500M in notes

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced after market close that it plans to raise $500 million from the sale of exchangeable senior notes to institutional investors. The senior notes are due in 2021 and are exchangeable...
BioCentury | May 12, 2014
Finance

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
BioCentury | Mar 3, 2014
Finance

Spreading six

Abingworth's sixth flagship fund likely will put more money towards the opposite ends of the firm's investment universe - start-ups and public companies. The new fund closed last week at £225 million ($375 million). Seven years...
Items per page:
1 - 10 of 38